Published • loading... • Updated
New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment
- XellSmart presented Phase I data for its off-the-shelf Parkinson’s disease cell therapy, XS411, at the International Congress of Parkinson’s Disease and Movement Disorders.
- ¹⁸F-DOPA PET imaging showed increased tracer uptake at the transplant site after XS411 treatment, indicating higher regional dopamine synthesis and metabolic capacity.
- The trial met its primary safety and tolerability goals, and XS411 was generally well tolerated.
- At six months, participants’ average OFF-state motor scores improved by more than 30 points, while daily good ON time increased by over five hours; all 30 planned participants were enrolled.
Insights by Ground AI
24 Articles
24 Articles
New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment
SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), one of the world's most prestigious…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left6Leaning Right3Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 27%
C 59%
14%
Factuality
To view factuality data please Upgrade to Premium
